Nicox S.A FR COX))), an international eye care company, today announced a series of presentations at major ophthalmology conferences, including the 2023 American Glaucoma Society (AGS) Annual Meeting and the 2023 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting.

Details of the lectures (all US local time)

AGS Annual Meeting 2023 – 2nd – 5th March 2023, Austin, TX, US

poster title: NCX 470, a Nitric Oxide Donating Bimatoprost, Demonstrates Non-Inferiority to Latanoprost in Phase 3 Mont Blanc Clinical Trial
Type: Top Poster Presentation Session
Date: March 3, 2023 from 7:30 a.m. to 8:30 a.m.
moderator: dr Robert Fechtner, Chair of the Department of Ophthalmology at SUNY Upstate Medical University in Syracuse, NY

ARV 2023 Annual Meeting – 23-27 April2023, New Orleans, L.A., US.

Poster title: NCX 1728, a nitric oxide (NO) donating phosphodiesterase type 5 inhibitor but not its des-nitro derivative (NCX 1880), improves ocular perfusion and improves photoreceptor function in rabbits with endothelin-1 (ET-1) induced ischemia/reperfusion injury of the optic disc and retina
Type: paper presentation
meeting title: Retina/RPE: New drugs, administration and mechanisms of action 2
Date: April 25, 2023 from 11:45 a.m. to 1:30 p.m
moderator: Corinna Galli, PhD, Nicox Research Institute

poster title: NCX 470, a nitric oxide (NO) donating bimatoprost, protects rabbit eyes from biochemical and functional changes associated with endothelin-1 (ET-1)-induced ischemia/reperfusion injury of the optic disc and retina
Type: Poster presentation
session title: Neuroprotective therapies
Date: April 25, 2023 from 8:45 a.m. to 10:45 a.m
moderator: Francesco Impagnatiello, PhD, Nicox Research Institute

NCX 470 is a novel nitric oxide (NO) donating bimatoprost currently in Phase 3 clinical development for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension….